Omnicell, Inc.

Hello and welcome to the OmniSol fiscal year and fourth quarter 2025 results. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. And if you would like to withdraw your question, press star one again. And please note that this call is being recorded. I will now turn the call over to Kathleen Lima, Senior VP, Investor Relations. You may begin.

Good morning and welcome to the OmniCell full year 2025 and fourth quarter financial results conference call. On the call with me today are Randall Lipps, OmniCell Chairman, President, CEO, and Founder, Baird Radford, Executive Vice President and Chief Financial Officer, and Nandi Njoku, Executive Vice President and Chief Operating Officer. This call will contain forward-looking statements, including statements related to financial projections or performance, and market or company outlook based on current expectations. These forward-looking statements speak only as of today or the date specified on the call. Actual results and other events may differ materially from those contemplated due to numerous factors that involve substantial risks and uncertainties. For more information, please refer to our press release issued today OmniCell's annual report on Form 10-K filed with the SEC on February 27, 2025, and in other more recent reports filed with the SEC. Except as required by law, we do not assume any obligation to update any forward-looking statements. During this call, we will discuss some non-GAAP financial measures. Reconciliations of these non-GAAP financial measures to the most comparable GAAP financial measures are included in our financial results press releases. Our results were released this morning, and our financial results press releases are always posted in the investor relations section of our website at ir.omnicell.com. With that, I will turn the call over to Randall. Randall?

Good morning, and welcome to OmniCell's fourth quarter 2025 earnings call. We are pleased to report a solid finish to 2025. fourth quarter total revenues, bookings, and ARR each coming in above the midpoint of our previous announced guidance ranges. We executed nicely in our core point-of-care business and saw strong demand for our flagship point-of-care connected devices, including XT-SEN, which drove our robust top-line performance during the quarter. We are happy to see the ongoing customer focus on our innovative solutions leading to recent wins at major health systems and government healthcare facilities. We continue to advance our transformation efforts into an end-to-end medication management platform technology company. Looking ahead, we remain focused on delivering innovative solutions that aim to continuously improve the customer experience and enable the autonomous pharmacy vision. We believe that our commitment to operational excellence as well as customer and patient-centric outcomes positions us to drive long-term value for all of our stakeholders. As we have outlined previously, we expect our future growth to continue to be driven by three core pillars, which include expanding our market presence, scaling reoccurring revenue, and accelerating our technology platform. Expanding our market presence. We're actively working to grow our product footprint across the inpatient and outpatient care environments, including nursing units, operating rooms, and a full spectrum of pharmacy settings. We believe that the recent customer wins and increased platform adoption underscore the strength of our solutions and the trust we are building across the healthcare continuum. As part of this expansion of market presence, we introduced TitanXT, our transformational enterprise-wide automation dispensing system at the ASHP annual meeting in December. TitanXT is designed to unify proven automation and powerful intelligence and will deliver a more efficient medication management experience to support a growing health system. With the TitanXT launch, We continue to focus on extending the power of Omnisphere, OmniCell's cloud-based, high-trust, certified medication management platform into inpatient nursing care areas. This should deliver greater control of medication inventory management for pharmacy while providing nurses with more confidence when administering medications. At the ASHP annual meeting, we connected with over 4,000 pharmacy leaders who had the opportunity to see firsthand how we are working to empower autonomous medication management to deliver improved patient outcomes, a superior clinical experience, and greater visibility and security. We are encouraged by the early positive feedback that we are receiving from pharmacists and nursing as our sales team discusses Titan XT and Omnisphere with customers. Scaling reoccurring revenue. We are focused on expanding our base of predictable recurring revenue through cloud-based offerings, software subscriptions, and revised service contracts, which is anticipated to provide greater predictability for our business while delivering long-term value to our customers. As Baird will discuss in a moment, our strong fourth quarter performance was driven in part by continued strength in annual recurring revenues. which exited the fourth quarter of 2025 at an annualized run rate of 636 million, an increase of 10% from our 2024 exit rate. Lastly, accelerating our technology platform, Omnisphere. Omnisphere is our cloud-native platform designed to unify all OmniCell products under a single, secure infrastructure intended to make it simpler, safer, and more connected to manage medications within a growing health system. Designed to be the connected backbone for medication management, Omnisphere offers a single command center for automation and intelligence that is engineered to provide enterprise-wide visibility into medications and supply inventory. As previously announced, Omnisphere achieved high-trust CSF I-1 certification in 2025, demonstrating our commitment to cybersecurity and adherence to high industry standards for data protection and medication management. Recognizing this recent example of our commitment to customer-centric solutions, OmniCell once again noted among the top 50 healthcare technology companies by the Healthcare Technology Report for a continuous focus on innovation that is designed to help healthcare organizations deliver safer and more precise care. We believe the power of Omnicel's products and services portfolio to support safety and efficiency across all care settings is resonating with the market as large health systems across the country select Omnicel during the quarter as their medication management partner. Competitive convergence during the fourth quarter of 2025 included leading health systems serving Louisiana, Mississippi, a large Texas-based academic health system, and a New England integrated health delivery network, all of whom have indicated that they plan to leverage OmniCell's central pharmacy automation, point-of-care dispensing solutions, and OmniCell's inventory optimization service in an effort to drive patient safety improve clinician and pharmacy staff efficiency, and support an optimized pharmacy supply chain. This was also another strong quarter for our point-of-care solutions, including XT Extend, which has helped to drive significant wins across the U.S. and Canada, including leading health systems in western New York and Honolulu, Hawaii, along with Canadian providers in British Columbia and Vancouver. During the fourth quarter, the Department of Veteran Affairs selected OmniSales point-of-care dispensing and IV workflow solutions to support medication management at a number of hospitals across their network. As we look at the broader economic environment influencing customers' capital decisions, we are encouraged by early reports from publicly traded health systems and industry reports which suggest increasing patient volumes and improving financial performance. While hospital fundamentals have been strong, some potential uncertainty still exists, particularly around regulations and tariffs. Nonetheless, I'm excited by the momentum we have coming out of 2025, driven by our commitment to empowering autonomous medication management. As hospitals and health systems continue to navigate the dynamic cost and regulatory environment, we remain dedicated to our mission to be their most trusted partner, helping empower them to achieve better patient outcomes, lower cost, and improve staff efficiency. Now, at this point, I'd like to turn the call over to our Chief Financial Officer, Baird Radford, for a review of our financial results. Baird?